Australia & South Korea Diabetic Foot Ulcer Market Size and Forecasts (2020 - 2030), Country Share, Trends, and Growth Opportunity Analysis Coverage By: Ulcer Type (Neuropathic Ulcers, Ischemic Ulcers, and Neuro-Ischemic Ulcers), Treatment Type (Advanced

Australia & South Korea Diabetic Foot Ulcer Market Size and Forecasts (2020 - 2030), Country Share, Trends, and Growth Opportunity Analysis Coverage By: Ulcer Type (Neuropathic Ulcers, Ischemic Ulcers, and Neuro-Ischemic Ulcers), Treatment Type (Advanced Wound Care Dressings, Biologics, and Therapy Device), Infection Severity (Mild, Moderate, and Severe), End User (Hospitals, Ambulatory Surgery Centers, and Home Care), and Country

The Australia & South Korea diabetic foot ulcer market is projected to reach US$ 313.53 million by 2030 from US$ 199.59 million in 2022; it is expected to grow at a CAGR of 5.8% from 2022 to 2030. The factors such as increasing prevalence of diabetes and related chronic wounds and the rise in geriatric population propel are expected to drive the Australia & South Korea diabetic foot ulcer market growth. Moreover, growing research activities to unveil novel wound treatment products is also expected to foster the Australia & South Korea diabetic foot ulcer market growth during the forecast period. However, the high cost of advanced wound care treatments may hinder the Australia & South Korea diabetic foot ulcer market growth.

Use of 3D Printing in Wound Care Management to Boost the Australia & South Korea Diabetic Foot Ulcer Market in Future

Skin tissue damage caused by various indications due to diabetes and vascular diseases significantly burdens the healthcare systems. 3D bioprinting is based on layer-based synthesis, wherein the newly generated cells and cell-based materials can be dispensed to mimic native tissues. Though the technology is still nascent, 3D printing can potentially revolutionize the wound care industry. Many companies are involved in developing new products involving ion-release biomaterials that promote angiogenesis for dermal regeneration. In addition, 3D bioprinting helps patch large wounds that are hard to heal with standard techniques. In July 2020, Startup Inventia Life Science Pty. Ltd. received two major funds from the Australian government to encourage the development of a robotic device that prints a patient’s skin cells directly onto a burn or wound. Thus, the use of 3D bioprinting technologies in ulcer or wound treatments is likely to emerge as a prominent trend in the diabetic foot ulcer market in the coming years.

Thus, such advancements are expected to foster diabetic foot ulcer and enhance the Australia & South Korea diabetic foot ulcer market growth in the coming years.

The Australia & South Korea diabetic foot ulcer market is segmented on the basis of ulcer type, treatment type, infection severity, end user, and country. Based on ulcer type, the Australia & South Korea diabetic foot ulcer market is segmented into neuropathic ulcers, ischemic ulcers, and neuro-ischemic ulcers. The neuro-ischemic ulcers segment held the largest share of the market in 2022, and it is anticipated to register the highest CAGR during the forecast period. Based on treatment type, is segmented into advanced wound care dressings, biologics, and therapy device. The advanced wound care dressings segment held the largest market share in 2022. The biologics segment is anticipated to register the highest CAGR of 6.4% during 2022–2030. Advanced wound care dressings are further segmented as alginate dressings, hydrofiber dressings, foam dressings, collagen dressings, film dressings, and others. Only standard-of-care therapy is often not sufficient to heal diabetic foot ulcer wounds and requires the subsequent or simultaneous application of adjuvant wound therapies, including biological skin substitutes. Biologics are developed from natural sources, including humans, animals, and microorganisms. Cell-based biological substitutes are used particularly for the treatment of wounds. Based on infection severity, is categorized into moderate, mild, and severe. The moderate segment held the largest market share in 2022 and the same segment is anticipated to register the highest CAGR during 2022–2030. Based on end user, the market is segmented into ambulatory surgical centers, hospitals, and home care. The hospital segment held the largest market share in 2022 and the same segment is anticipated to register the highest CAGR during 2022–2030.

The World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), International Working Group on the Diabetic Foot (IWGDF), US Food and Drug Administration (FDA), and Ministry of Food and Drug Safety (MFDS) are among some of the primary and secondary sources referred to while preparing the report on the Australia & South Korea diabetic foot ulcer market.